Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
Anxiety · people at high risk of or withcardiovascular disease
1 finding from 1 review
Depression, change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
Perceived stress · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
General well‐being · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking cessation · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety · people at high risk of or withcardiovascular disease
1 finding from 1 review
Depression, change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
Perceived stress, change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
General well‐being · people at high risk of or withcardiovascular disease
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking cessation · people at high risk of or withcardiovascular disease
Mindfulness‐based interventions (MBIs) showed no clear difference in smoking cessation compared with active comparators (low certainty).
1 finding from 1 review
Overall survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
Epidermal growth factor showed no clear difference in survival rates at 3 years compared with best supportive care (low certainty).
1 finding from 1 review
Survival rates at 5 years · People with advanced non‐small cell lung cancer
Epidermal growth factor may leads to higher survival rates at 5 years compared with best supportive care (low certainty).
1 finding from 1 review
Health‐related quality of life · People with advanced non‐small cell lung cancer
It is very uncertain whether epidermal growth factor changes health‐related quality of life compared with best supportive care (very low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in survival rates at 3 years compared with chemotherapy alone (low certainty).
1 finding from 1 review